CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: May 6, 2009
Result type: Reports
Project Number: SR0165-000
Product Line: Reimbursement Review

Generic Name: Eplerenone

Brand Name: Inspra

Manufacturer: Pfizer Canada Inc.

Therapeutic Area: Post myocardial infarction

Indications: Post myocardial infarction

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: November 25, 2009

Recommendation Type: Do not list